WO2002039981A1 - Microgranules a base de principe actif et leur procede de fabrication - Google Patents
Microgranules a base de principe actif et leur procede de fabrication Download PDFInfo
- Publication number
- WO2002039981A1 WO2002039981A1 PCT/FR2001/003584 FR0103584W WO0239981A1 WO 2002039981 A1 WO2002039981 A1 WO 2002039981A1 FR 0103584 W FR0103584 W FR 0103584W WO 0239981 A1 WO0239981 A1 WO 0239981A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- core
- active principle
- binding agent
- microgranule
- coated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
Definitions
- the invention relates to a microgranule consisting of a coated nucleus comprising at least one active principle. It also relates to the process for manufacturing said micro granule as well as to pharmaceutical compositions incorporating a plurality of said microgranule.
- the document WO 95/22319 describes a method of manufacturing by extrusion / spheronization of fine particles based on active principle.
- the fine particles obtained have a size between 50 ⁇ m and 1 mm.
- the examples describe particles of size equal to 300 ⁇ m comprising up to 72% of active principle in the presence of at least three excipients including in particular an extrusion agent.
- these same examples and in particular the formulation 1 c shows that this process does not make it possible to obtain fine particles of this order of size with a high concentration of active principle, equal to 95%.
- the fine particles obtained at the end of the process have a surface which is too irregular to allow satisfactory subsequent treatment, the coating aiming to mask the taste of the active principle requiring, for example, a high coating rate.
- microgranules designated here by the expression "fine granules". It is indicated that at least 75% of the population of microgranules has a size of between 1 and 500 ⁇ m. No information is given concerning the concentration of active principle within the microgranule.
- microgranules of active principle and 'in particular of ferritin as well as their manufacturing process.
- These microgranules consist of a core comprising a first coating obtained by spraying an aqueous suspension of active principle, the cohesion of said first coating with the core being ensured by uniform dispersion, between each spraying step, of small quantities of talc ( see in particular page 7, example 3).
- the core thus coated also has a second coating, the nature of which depends on the release characteristics of the
- the core itself can have two different shapes.
- the core consists exclusively of inert material, for example of the sucrose type.
- the core is in the form of a granule based on binding agent (for example starch) and active principle in proportions of 50/50.
- the manufacturing process and the microgranule thus obtained have a number of drawbacks.
- this requires at least four stages, which are the manufacturing of the core, then, alternatively, the application of the first coating, and the dispersion of talc and finally the application of the second coating.
- Such a process is particularly long and cannot be carried out continuously.
- the cohesion of the first coating on the core is not always homogeneous, leading to coated cores having an irregular surface and thereby increasing the amount of material necessary for the second coating.
- the microgranule it is indicated that the core before coating has a size of between 0.3 and 0.5 millimeters (see examples) for a concentration of active principle representing only 50% of the mass of the core .
- the first problem which the invention proposes to solve is to provide microgranules, the core of which, before coating the functional layer or layers, conferring on the microgranule the characteristics of release of the active principle and / or masking of desired taste, is as concentrated as possible in active ingredient.
- the second problem which the invention proposes to solve is to provide a microgranule, the core of which, before coating of the functional layer or layers, is substantially spherical so as to decrease its specific surface and thus reduce the quantity of material necessary for the 'subsequent coating.
- the third problem which the invention proposes to solve is to provide a microgranule, the core of which, before coating of the functional layer or layers, has the smallest possible size, advantageously a median size of less than 500 ⁇ m.
- the invention therefore relates to a microgranule consisting of a core coated with at least one coating layer, said coated core comprising at least one active principle.
- This microgranule is characterized in that the core and said coating layer each contain between 80 and 95%, by weight of active principle, the complement to 100% consisting of at least one binding agent, and in that the coated core has a substantially spherical shape.
- the core and the coating layer each contain between 85 and 93%, advantageously 90% by weight of active principle.
- the complement to 100% by weight of the core and the coating layer consists exclusively of a binding agent.
- binding agent will be determined as a function not only of its capacity to bind the particles of active principle to each other within the coated core but also of the desired functional characteristics of the coated core, whether in the presence or in the presence of absence of subsequent functional coating.
- functional characteristics is meant in particular but not limited to, the taste masking properties and / or release (modified or not) of the active principle.
- the microgranule of the invention already has specific characteristics thus making it possible to reduce the thickness of the subsequent coating and therefore the size of the final microgranule.
- the binding agent is chosen from the group comprising ethyl cellulose,
- HPC hydroxypropylcellulose
- CMC carboxymethyl cellulose
- HPMC hydroxypropylmethylcellulose
- acrylic polymers methacrylic polymers, amonio-methacrylate copolymer, polyacrylate, metacrylic acid copolymer and polyvinylpyrrolidone.
- the binding agent contained in the coating layer and that contained in the core can be identical or different.
- Another objective of the invention is to reduce the size of the coated microgranule before coating of the possible subsequent functional layer.
- the high titer of the microgranules of the invention makes it possible to partially fulfill this objective.
- the size of the particles of active principle varies between 10 and 30 ⁇ .
- the size of the coated microgranules of the invention before possible subsequent coating is less than 500 ⁇ m, advantageously between 200 and 300 ⁇ m.
- the coated core constituting the microgranule of the invention may comprise an additional functional coating, generally of polymeric origin, the nature of which will depend on the desired characteristics of the final formulation and in particular of taste masking and / or of modified or unmodified release of active principle.
- the microgranules of the invention also have the advantage of being substantially spherical, thus having a reduced specific surface making it possible to coat a subsequent layer of raw material in reduced quantities compared to microgranules known from the prior art.
- This subsequent layer preferably comprises a polymer, the application of which on the microgranules will make it possible to achieve the desired final characteristics.
- microgranules of the invention can be used in different dosage forms such as in particular sachets, capsules, liquid suspensions, dry suspensions intended for an extemporaneous reconstitution. They can also enter into the composition of orodispersible tablets or not.
- the reduced size of the microgranules of the invention makes it possible to reduce the proportion of compression excipients (for example diluents) necessary for obtaining a homogeneous mixture before compression, which makes it possible to have a final shape. smaller in size and weight compared to known tablets of the same type and also to reduce the compressive forces.
- the invention relates more particularly to tablets of the multiparticulate type with rapid disintegration such as those described by the Applicant in document FR-A-2 679 451, and of the type with rapid hydrodispersibility (fast dispersible) comprising the microgranules previously described.
- the subject of the invention is also the process for manufacturing the microgranules described above, according to which: in a first step, a solution of granulation comprising at least one binding agent in a solvent until a nucleus is obtained; 4 then, in a second step, the core formed by spraying is coated with a suspension or coating solution based on particles of active principle and 5 of binding agent, the coated core obtained then having a substantially spherical shape.
- a step of drying the cores obtained is inserted between the first and the second step. 10
- the process can be carried out continuously or discontinuously.
- the solvent in which the binding agent is dissolved will be determined according to the very nature of the binding agent and will be chosen from aqueous or organic solvents, alone or in combination.
- the size of the particles of active principle used in the first step is between 10 and 30 micrometers, advantageously 25 micrometers, while the size of the particles of active principle used in the second step is between 10 and 20 micrometers, advantageously less than 15 micrometers.
- particle sizes of active ingredient can be obtained by any process known to those skilled in the art, in particular micronization or grinding.
- the size of the particles of active principle used in the first step is identical to the size of those used in the second step.
- the active ingredient / binding agent ratio is constant during the first and second steps, advantageously equal to 90/10. Consequently, the active ingredient / binding agent ratio is constant during the first and second steps, advantageously equal to 90/10. Consequently, the active ingredient / binding agent ratio is constant during the first and second steps, advantageously equal to 90/10. Consequently, the active ingredient / binding agent ratio is constant during the first and second steps, advantageously equal to 90/10. Consequently, the active ingredient / binding agent ratio is constant during the first and second steps, advantageously equal to 90/10. Consequently, the active ingredient / binding agent ratio is constant during the first and second steps, advantageously equal to 90/10. Consequently, the active ingredient / binding agent ratio is constant during the first and second steps, advantageously equal to 90/10. Consequently, the active ingredient / binding agent ratio is constant during the first and second steps, advantageously equal to 90/10. Consequently, the active ingredient / binding agent ratio is constant during the first and second steps, advantageously equal to 90/10. Consequently, the active ingredient / binding agent ratio is constant during
- 35 second stage can be stopped as soon as the desired size of the microgranule, less than
- a third step at least one additional coating solution is sprayed, the composition of which is chosen as a function of the taste masking and / or release of active principle characteristics desired.
- the process of the invention is carried out in a fluidized air bed, advantageously by the bottom spray technique.
- the parameters of the fluidized bed do not have any particular characteristics and will be adjusted in the usual manner by a person skilled in the art.
- 1,200 g of micronized ibuprofen (25 ⁇ ) and 120 g of HPMC 606 are mixed together in 3,080 g of purified water, still stirring until complete dissolution of hydroxypropyl methylcellulose.
- ibuprofen with a particle size equal to 25 micrometers 400 g are introduced into a fluidized bed device of the GLATT GPCG 1 type equipped with a Bottom Spray tank while maintaining the active principle at a temperature sufficient to avoid sticking while keeping the mass moist. .
- the granulation solution prepared above is then sprayed until a nucleus having a median particle size of approximately 100 micrometers is obtained.
- the coating suspension based on active principle is sprayed continuously until a granule having a median particle size of between 250 and 300 micrometers is obtained.
- a polymer dispersion of ethyl cellulose and HPMC and syloid is applied to the coated core in order to mask the taste of the active principle.
- Example 1 is repeated, replacing the HPMC with Eudragit ® E 100 and the purified water with Ethanol.
- Eudragit ® is chosen as a binding agent, but also for its function as an agent masking the taste of the active principle, while allowing its immediate release. This therefore makes it possible to improve the masking of taste from the granulation stage, before the optional stage of functional coating.
- a 5% (w / w) PNP K90 granulation solution is prepared in ethanol.
- the granulation solution previously obtained is then sprayed. After the core thus formed has dried, the coating suspension based on active principle is sprayed continuously until a granule having a median particle size of approximately 257 ⁇ m is obtained.
- the coated cores are sprayed with a 12.5% (w / w) polymeric solution of Eudragit ® El 00 (manufactured by Rohm) in ethanol.
- the equivalent of 10% (w / w calculated as dry polymer) of the mass of the coated cores is applied for the masking of taste.
- coated microgranules whose coated core has a very small size, less than 300 micrometers, facilitating the functional coating and subsequent shaping.
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002542356A JP4234427B2 (ja) | 2000-11-16 | 2001-11-15 | 活性成分をベースとする微小顆粒およびその製造方法 |
AU2002223074A AU2002223074B2 (en) | 2000-11-16 | 2001-11-15 | Microgranules based on active principle and method for making same |
EP01996363A EP1333812B1 (fr) | 2000-11-16 | 2001-11-15 | Microgranules a base de principe actif et leur procede de fabrication |
DK01996363T DK1333812T3 (da) | 2000-11-16 | 2001-11-15 | Mikrogranulat baseret på aktivt stof og fremgangsmåde til at fremstille samme |
CA2427899A CA2427899C (fr) | 2000-11-16 | 2001-11-15 | Microgranules a base de principe actif et leur procede de fabrication |
MXPA03004300A MXPA03004300A (es) | 2000-11-16 | 2001-11-15 | Microangulos basados en principio activo y metodo para su fabricacion. |
US10/416,848 US7829122B2 (en) | 2000-11-16 | 2001-11-15 | Microgranules based on active principle and method for making same |
AU2307402A AU2307402A (en) | 2000-11-16 | 2001-11-15 | Microgranules based on active principle and method for making same |
DE60133028T DE60133028T2 (de) | 2000-11-16 | 2001-11-15 | Mikrogranulat auf wirkstoffbasis und verfahren zu seiner herstellung |
HK04105869D HK1063017A1 (en) | 2000-11-16 | 2004-08-06 | Microgranules based on active principle and methodfor making same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0014803A FR2816507B1 (fr) | 2000-11-16 | 2000-11-16 | Microgranules a base de principe actif, procede de fabrication et compositons pharmaceutiques integrant lesdits microgranules |
FR00.14803 | 2000-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002039981A1 true WO2002039981A1 (fr) | 2002-05-23 |
Family
ID=8856551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2001/003584 WO2002039981A1 (fr) | 2000-11-16 | 2001-11-15 | Microgranules a base de principe actif et leur procede de fabrication |
Country Status (15)
Country | Link |
---|---|
US (1) | US7829122B2 (fr) |
EP (1) | EP1333812B1 (fr) |
JP (1) | JP4234427B2 (fr) |
CN (1) | CN1222277C (fr) |
AT (1) | ATE387187T1 (fr) |
AU (2) | AU2307402A (fr) |
CA (1) | CA2427899C (fr) |
DE (1) | DE60133028T2 (fr) |
DK (1) | DK1333812T3 (fr) |
ES (1) | ES2300384T3 (fr) |
FR (1) | FR2816507B1 (fr) |
HK (1) | HK1063017A1 (fr) |
MX (1) | MXPA03004300A (fr) |
PT (1) | PT1333812E (fr) |
WO (1) | WO2002039981A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2850576A1 (fr) * | 2003-02-05 | 2004-08-06 | Ethypharm Sa | Composition comprenant un melange de principes actifs, et procede de preparation |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2796840B1 (fr) * | 1999-07-26 | 2003-06-20 | Ethypharm Lab Prod Ethiques | Comprimes faiblement doses et procede de preparation |
EP1279402B1 (fr) * | 2001-07-26 | 2006-11-29 | Ethypharm | Granules enrobés d'allylamines ou de benzlyamines antimycotiques, procédé de préparation, et comprimés orodispersibles contenant les granules enrobés |
FR2831820B1 (fr) * | 2001-11-05 | 2004-08-20 | Ethypharm Sa | Comprime orodispersible presentant une grande homogeneite et son procede de preparation |
US6723348B2 (en) * | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
CA2533150C (fr) * | 2003-07-25 | 2013-03-12 | Warner Chilcott Company, Inc. | Complexe metallique de doxycycline en forme posologique solide |
US8758816B2 (en) | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
US20070020330A1 (en) | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
PL2486942T3 (pl) | 2004-11-24 | 2019-05-31 | Meda Pharmaceuticals Inc | Kompozycje zawierające azelastynę oraz sposoby ich stosowania |
WO2006078925A2 (fr) * | 2005-01-21 | 2006-07-27 | Warner Chilcott Company, Inc. | Complexe metallique de tetracycline sous forme de dosage solide |
CN101912360A (zh) * | 2010-07-13 | 2010-12-15 | 山东达因海洋生物制药股份有限公司 | 布洛芬混悬液及其制备方法 |
PL2672981T3 (pl) | 2011-02-11 | 2018-09-28 | Zx Pharma, Llc | Wielocząstkowe preparaty l-mentolu i powiązane sposoby |
US8911780B2 (en) | 2011-02-11 | 2014-12-16 | Zx Pharma, Llc | Multiparticulate L-menthol formulations and related methods |
US8808736B2 (en) | 2011-02-11 | 2014-08-19 | Zx Pharma, Llc | Enteric coated multiparticulate controlled release peppermint oil composition and related methods |
DE102012007671A1 (de) | 2012-04-16 | 2013-10-17 | Acino Pharma Ag | Pellets mit hohem Wirkstoffgehalt |
FR2999432B1 (fr) | 2012-12-17 | 2014-12-12 | Ethypharm Sa | Comprimes orodispersibles obtenus par compression moulage |
LT2988824T (lt) | 2013-04-23 | 2019-02-25 | Zx Pharma, Llc | Žarnyno turiniui atspariu dangalu padengta multidalelių kompozicija su baltyminiu pagalbiniu dangalu |
KR102019645B1 (ko) * | 2019-02-21 | 2019-09-09 | 한국화학연구원 | 염기성오염물질 제거용 비드 및 이의 제조방법 |
CN111184694A (zh) * | 2020-01-19 | 2020-05-22 | 广东青云山药业有限公司 | 一种口腔速溶颗粒的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4957746A (en) * | 1984-06-29 | 1990-09-18 | Roberto Valducci | Process for preparing etofibrate or similar compounds containing sustained release microgranules and products thus obtained |
US5476667A (en) * | 1990-10-16 | 1995-12-19 | Kabi Pharmacia Ab | Method for drug formulation and a pharmaceutical composition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3558768A (en) * | 1969-12-19 | 1971-01-26 | Sterling Drug Inc | Sustained release pharmaceutical compositions |
IT1115596B (it) | 1978-03-13 | 1986-02-03 | Bayer Italia Spa | Metodo per la preparazione di microgranuli gastoresistenti ed enterosolubili di sostanze farmaceutiche,in particolare di sostanze proteiche e microgranuli preparati con detto metodo |
US4248858A (en) * | 1979-08-09 | 1981-02-03 | American Home Products Corporation | Sustained release pharmaceutical compositions |
JPS63188621A (ja) * | 1987-01-30 | 1988-08-04 | Taisho Pharmaceut Co Ltd | 矯味経口製剤 |
US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
US4853229A (en) * | 1987-10-26 | 1989-08-01 | Alza Corporation | Method for adminstering tiny pills |
US5344657A (en) * | 1988-04-27 | 1994-09-06 | Elf Sanofi | Microbeads of diltiazem, a process for their manufacture and a substained-release pharmaceutical composition containing them |
JP3078859B2 (ja) | 1990-02-23 | 2000-08-21 | 武田薬品工業株式会社 | 安定な放出制御性製剤用コーティング剤 |
EP0744941B1 (fr) | 1994-02-16 | 2003-06-04 | Abbott Laboratories | Mode de preparation de formulations pharmaceutiques a fines particules |
US5837292A (en) * | 1996-07-03 | 1998-11-17 | Yamanouchi Europe B.V. | Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug |
-
2000
- 2000-11-16 FR FR0014803A patent/FR2816507B1/fr not_active Expired - Lifetime
-
2001
- 2001-11-15 PT PT01996363T patent/PT1333812E/pt unknown
- 2001-11-15 DK DK01996363T patent/DK1333812T3/da active
- 2001-11-15 CN CN01820962.9A patent/CN1222277C/zh not_active Expired - Lifetime
- 2001-11-15 JP JP2002542356A patent/JP4234427B2/ja not_active Expired - Fee Related
- 2001-11-15 EP EP01996363A patent/EP1333812B1/fr not_active Expired - Lifetime
- 2001-11-15 AT AT01996363T patent/ATE387187T1/de active
- 2001-11-15 DE DE60133028T patent/DE60133028T2/de not_active Expired - Lifetime
- 2001-11-15 CA CA2427899A patent/CA2427899C/fr not_active Expired - Lifetime
- 2001-11-15 ES ES01996363T patent/ES2300384T3/es not_active Expired - Lifetime
- 2001-11-15 AU AU2307402A patent/AU2307402A/xx active Pending
- 2001-11-15 WO PCT/FR2001/003584 patent/WO2002039981A1/fr active IP Right Grant
- 2001-11-15 MX MXPA03004300A patent/MXPA03004300A/es active IP Right Grant
- 2001-11-15 AU AU2002223074A patent/AU2002223074B2/en not_active Ceased
- 2001-11-15 US US10/416,848 patent/US7829122B2/en active Active
-
2004
- 2004-08-06 HK HK04105869D patent/HK1063017A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4957746A (en) * | 1984-06-29 | 1990-09-18 | Roberto Valducci | Process for preparing etofibrate or similar compounds containing sustained release microgranules and products thus obtained |
US5476667A (en) * | 1990-10-16 | 1995-12-19 | Kabi Pharmacia Ab | Method for drug formulation and a pharmaceutical composition |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2850576A1 (fr) * | 2003-02-05 | 2004-08-06 | Ethypharm Sa | Composition comprenant un melange de principes actifs, et procede de preparation |
WO2004069135A2 (fr) * | 2003-02-05 | 2004-08-19 | Ethypharm | Composition comprenant un melange de principes actifs, et procede pour la preparer |
WO2004069135A3 (fr) * | 2003-02-05 | 2004-10-28 | Ethypharm Sa | Composition comprenant un melange de principes actifs, et procede pour la preparer |
EA010972B1 (ru) * | 2003-02-05 | 2008-12-30 | Этифарм | Композиция, содержащая смесь активных начал, и способ ее получения |
US7846460B2 (en) | 2003-02-05 | 2010-12-07 | Ethypharm | Composition comprising a mixture of active principles, and method of preparation |
Also Published As
Publication number | Publication date |
---|---|
EP1333812A1 (fr) | 2003-08-13 |
JP2004517064A (ja) | 2004-06-10 |
PT1333812E (pt) | 2008-03-17 |
FR2816507A1 (fr) | 2002-05-17 |
AU2002223074B2 (en) | 2005-03-10 |
CA2427899A1 (fr) | 2002-05-23 |
AU2307402A (en) | 2002-05-27 |
CN1481235A (zh) | 2004-03-10 |
US20040101568A1 (en) | 2004-05-27 |
FR2816507B1 (fr) | 2003-02-28 |
MXPA03004300A (es) | 2004-09-10 |
US7829122B2 (en) | 2010-11-09 |
DK1333812T3 (da) | 2008-03-31 |
ATE387187T1 (de) | 2008-03-15 |
DE60133028D1 (de) | 2008-04-10 |
DE60133028T2 (de) | 2009-03-12 |
CN1222277C (zh) | 2005-10-12 |
EP1333812B1 (fr) | 2008-02-27 |
ES2300384T3 (es) | 2008-06-16 |
CA2427899C (fr) | 2011-05-10 |
HK1063017A1 (en) | 2004-12-10 |
JP4234427B2 (ja) | 2009-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1333812B1 (fr) | Microgranules a base de principe actif et leur procede de fabrication | |
CA2375600C (fr) | Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif | |
EP1496869B1 (fr) | Particules enrobees a liberation prolongee et comprimes les contenant | |
EP1100467A1 (fr) | Procede de fabrication de particules de gabapentine ou de pregabaline enrobees | |
EP0939626B1 (fr) | Forme galenique a liberation prolongee de milnacipran | |
JPH07173050A (ja) | 球状核、球形顆粒およびその製造方法 | |
EP2050445A2 (fr) | Composition pharmaceutique de fénofibrate présentant une biodisponibilité élevée et son procédé de préparation | |
CH667008A5 (fr) | Procede pour le traitement de formes de dosage pharmaceutiques. | |
CA2374356C (fr) | Granules contenant une substance vegetale et leur procede de preparation | |
FR2790668A1 (fr) | Granules contenant une substance vegetale et leur procede de preparation | |
EP2435042B1 (fr) | Procede de preparation de particules creuses et leurs applications | |
EP1686966B1 (fr) | Comprimes faiblement doses a reseau de polymeres | |
EP1549298B1 (fr) | Spheroides procede de preparation et compositions pharmaceutiques | |
FR2769854A1 (fr) | Nouveau procede d'obtention de microspheres et les produits ainsi realises | |
EP1928408B1 (fr) | Comprimes orodispersibles de principes actifs amers | |
JP2541835B2 (ja) | 持続放出型薬理組成物の製法およびこれにより得られる組成物 | |
WO2021094697A1 (fr) | Procédé de fabrication d'une composition pharmaceutique à administration orale et à délivrance colonique | |
FR2620026A2 (fr) | Forme galenique comprenant des microparticules et son procede de preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2427899 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001996363 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 704/DELNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002223074 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/004300 Country of ref document: MX Ref document number: 2002542356 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10416848 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018209629 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001996363 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002223074 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001996363 Country of ref document: EP |